Development of a recombinant, chimeric tetravalent dengue vaccine candidate

Vaccine

Volumn 33, Issue 50, 2015, Pages 7112-7120

  Osorio, Jorge E ^a   Partidos, Charalambos D ^a   Wallace, Derek ^a   Stinchcomb, Dan T ^a  

^a Takeda Vaccines   (United States)

Author keywords

Dengue fever; Dengue virus; Vaccine development

Indexed keywords

CD8 ANTIGEN; DENGUE VACCINE; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5; RECOMBINANT VACCINE; LIVE VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHIMERA; CONTROLLED CLINICAL TRIAL (TOPIC); DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EYE PAIN; FATIGUE; FEVER; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; MYALGIA; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOPHOBIA; PRIMATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SEROCONVERSION; SIDE EFFECT; VIREMIA; VIRUS GENOME; VOMITING; ADAPTIVE IMMUNITY; ADVERSE DRUG REACTION; ANIMAL; BLOOD; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; INTRADERMAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MOUSE; PRECLINICAL STUDY; SURVIVAL ANALYSIS;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DENGUE; DENGUE VACCINES; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; INJECTIONS, INTRADERMAL; MICE; PRIMATES; SURVIVAL ANALYSIS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84952637821     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.11.022     Document Type: Article

References (56)

1. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J., et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010, 8(December (12 Suppl)):S7-S16.
2. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature 2013, 496(April (7446)):504-507.
3. Halstead S.B. Dengue virus-mosquito interactions. Annu Rev Entomol 2008, 53:273-291.
4. Guzman M.G., Alvarez M., Halstead S.B. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 2013, 158(July (7)):1445-1459.
5. Brady O.J., Gething P.W., Bhatt S., Messina J.P., Brownstein J.S., Hoen A.G., et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLOS Negl Trop Dis 2012, 6(8):e1760.
6. Teixeira M.G., Siqueira J.B., Ferreira G.L., Bricks L., Joint G. Epidemiological trends of dengue disease in Brazil (2000-2010): a systematic literature search and analysis. PLOS Negl Trop Dis 2013, 7(12):e2520.
7. Lorenzi O.D., Gregory C.J., Santiago L.M., Acosta H., Galarza I.E., Hunsperger E., et al. Acute febrile illness surveillance in a tertiary hospital emergency department: comparison of influenza and dengue virus infections. Am J Trop Med Hyg 2013, (February).
8. Guzman M.G., Kouri G. Dengue: an update. Lancet Infect Dis 2002, 2(January (1)):33-42.
9. Chawla P., Yadav A., Chawla V. Clinical implications and treatment of dengue. Asian Pac J Trop Med 2014, 7(March (3)):169-178.
10. Lum L.C., Suaya J.A., Tan L.H., Sah B.K., Shepard D.S. Quality of life of dengue patients. Am J Trop Med Hyg 2008, 78(June (6)):862-867.
11. Martelli C.M., Nascimento N.E., Suaya J.A., Siqueira J.B., Souza W.V., Turchi M.D., et al. Quality of life among adults with confirmed dengue in Brazil. Am J Trop Med Hyg 2011, 85(October (4)):732-738.
12. WHO Dengue guidelines for diagnosis, treatment, prevention and control. World Health Organization (WHO) and the Special Programme for Research and Training in Tropical Diseases (TDR), France, editor. 3rd ed. 2009, World Health Organization, Geneva.
13. Cedillo-Barron L., Garcia-Cordero J., Bustos-Arriaga J., Leon-Juarez M., Gutierrez-Castaneda B. Antibody response to dengue virus. Microbes Infect/Institut Pasteur 2014, 16(September (9)):711-720.
14. de Alwis R., Beltramello M., Messer W.B., Sukupolvi-Petty S., Wahala W.M., Kraus A., et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 2011, 5(June (6)):e1188.
15. Weiskopf D., Sette A. T-cell immunity to infection with dengue virus in humans. Front Immunol 2014, 5:93.
16. + T cells. Proc Natl Acad Sci U S A 2013, 110(May (22)):E2046-E2053.
17. Hatch S., Endy T.P., Thomas S., Mathew A., Potts J., Pazoles P., et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 2011, 203(May (9)):1282-1291.
18. + T cells. J Immunol 2009, 182(April (8)):4865-4873.
19. + T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. J Immunol 2014, 193(October (8)):4117-4124.
20. Villar L., Dayan G.H., Arredondo-Garcia J.L., Rivera D.M., Cunha R., Deseda C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015, 372(January (2)):113-123.
21. Capeding M.R., Tran N.H., Hadinegoro S.R., Ismail H.I., Chotpitayasunondh T., Chua M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014, 384(October (9951)):1358-1365.
22. Bravo L., Roque V.G., Brett J., Dizon R., L'Azou M. Epidemiology of dengue disease in the Philippines (2000-2011): a systematic literature review. PLOS Negl Trop Dis 2014, 8(November (11)):e3027.
23. Limkittikul K., Brett J., L'Azou M. Epidemiological trends of dengue disease in Thailand (2000-2011): a systematic literature review. PLOS Negl Trop Dis 2014, 8(November (11)):e3241.
24. Dantes H.G., Farfan-Ale J.A., Sarti E. Epidemiological trends of dengue disease in Mexico (2000-2011): a systematic literature search and analysis. PLOS Negl Trop Dis 2014, 8(November (11)):e3158.
25. Mohd-Zaki A.H., Brett J., Ismail E., L'Azou M. Epidemiology of dengue disease in Malaysia (2000-2012): a systematic literature review. PLOS Negl Trop Dis 2014, 8(November (11)):e3159.
26. L'Azou M., Taurel A.F., Flamand C., Quenel P. Recent epidemiological trends of dengue in the French territories of the Americas (2000-2012): a systematic literature review. PLOS Negl Trop Dis 2014, 8(November (11)):e3235.
27. Williams M., Mayer S.V., Johnson W.L., Chen R., Volkova E., Vilcarromero S., et al. Lineage II of Southeast Asian/American DENV-2 is associated with a severe dengue outbreak in the Peruvian Amazon. Am J Trop Med Hyg 2014, 91(September (3)):611-620.
28. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000, 81(January (1)):2-9.
29. Kouri G.P., Guzman M.G., Bravo J.R., Triana C. Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull World Health Organ 1989, 67(4):375-380.
30. Osorio J.E., Huang C.Y., Kinney R.M., Stinchcomb D.T. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011, 29(September (42)):7251-7260.
31. Huang C.Y., Butrapet S., Tsuchiya K.R., Bhamarapravati N., Gubler D.J., Kinney R.M. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 2003, 77(November (21)):11436-11447.
32. Osorio J.E., Brewoo J.N., Silengo S.J., Arguello J., Moldovan I.R., Tary-Lehmann M., et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am J Trop Med Hyg 2011, 84(June 6):978-987.
33. Ambuel Y., Young G., Brewoo J.N., Paykel J., Weisgrau K.L., Rakasz E.G., et al. A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates. Front Immunol 2014, 5:263.
34. Henriques H.R., Rampazo E.V., Goncalves A.J., Vicentin E.C., Amorim J.H., Panatieri R.H., et al. Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge. PLOS Negl Trop Dis 2013, 7(7):e 2330.
35. Huang S.S., Li I.H., Hong P.D., Yeh M.K. Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine-loaded microspheres against dengue 2 virus. Int J Nanomed 2013, 8:3161-3169.
36. Monath T.P. Stability of yellow fever vaccine. Dev Biol Stand 1996, 87:219-225.
37. Wiggan O., Livengood J.A., Silengo S.J., Kinney R.M., Osorio J.E., Huang C.Y., et al. Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines. Vaccine 2011, 29(October (43)):7456-7462.
38. Huang C.Y., Kinney R.M., Livengood J.A., Bolling B., Arguello J.J., Luy B.E., et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis 2013, 7(May (5)):e2243.
39. Brault A.C., Kinney R.M., Maharaj P.D., Green E.N., Reisen W.K., Huang C.Y. Replication of the primary dog kidney-53 dengue 2 virus vaccine candidate in Aedes aegypti is modulated by a mutation in the 5' untranslated region and amino acid substitutions in nonstructural proteins 1 and 3. Vector Borne Zoonotic Dis 2011, 11(6):683-689.
40. Johnson A.J., Roehrig J.T. New mouse model for dengue virus vaccine testing. J Virol 1999, 73(January (1)):783-786.
41. Zompi S., Harris E. Animal models of dengue virus infection. Viruses 2012, 4(January (1)):62-82.
42. Sarathy V.V., White M., Li L., Gorder S.R., Pyles R.B., Campbell G.A., et al. A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease. J Virol 2015, 89(January (2)):1254-1266.
43. Milligan G.N., Sarathy V.V., Infante E., Li L., Campbell G.A., Beatty P.R., et al. A dengue virus type 4 model of disseminated lethal infection in AG129 mice. PLOS ONE 2015, 10(5):e4760125.
44. Brewoo J.N., Kinney R.M., Powell T.D., Arguello J.J., Silengo S.J., Partidos C.D., et al. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine 2011, 30(February (8)):1513-1520.
45. Fuchs J., Chu H., O'Day P., Pyles R., Bourne N., Das S.C., et al. Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice. Vaccine 2014, 32(November (48)):6537-6543.
46. Kwissa M., Nakaya H.I., Onlamoon N., Wrammert J., Villinger F., Perng G.C., et al. Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. Cell Host Microbe 2014, 16(July (1)):115-127.
47. Costa V.V., Fagundes C.T., Souza D.G., Teixeira M.M. Inflammatory and innate immune responses in dengue infection: protection versus disease induction. Am J Pathol 2013, 182(June (6)):1950-1961.
48. Osorio J.E., Velez I.D., Thomson C., Lopez L., Jimenez A., Haller A.A., et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis 2014, 14(September (9)):830-838.
49. George S.L., Wong M.A., Dube T.J., Boroughs K.L., Stovall J.L., Luy B.E., et al. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded Phase 1 clinical trial. J Infect Dis 2015, 19(March).
50. Whitehorn J., Kien D.T., Nguyen N.M., Nguyen H.L., Kyrylos P.P., Carrington L.B., et al. Comparative susceptibility of Aedes albopictus and Aedes aegypti to dengue virus infection after feeding on blood of viremic humans: implications for public health. J Infect Dis 2015, 17(March).
51. Nguyet M.N., Duong T.H., Trung V.T., Nguyen T.H., Tran C.N., Long V.T., et al. Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes. Proc Natl Acad Sci U S A 2013, 110(May (22)):9072-9077.
52. Brewoo J.N., Kinney R.M., Powell T.D., Arguello J.J., Silengo S.J., Partidos C.D., et al. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine 2012, 30(February (8)):1513-1520.
53. WHO Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses 2007, World Health Organization (WHO), Geneva, Switzerland.
54. + T-cell responses in flavivirus-naive individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate. J Infect Dis 2015, 5(May).
55. Butrapet S., Huang C.Y., Pierro D.J., Bhamarapravati N., Gubler D.J., Kinney R.M. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3. J Virol 2000, 74(April (7)):3011-3019.
56. Brault A.C., Kinney R.M., Maharaj P.D., Green E.N., Reisen W.K., Huang C.Y. Replication of the primary dog kidney-53 dengue 2 virus vaccine candidate in Aedes aegypti is modulated by a mutation in the 5' untranslated region and amino acid substitutions in nonstructural proteins 1 and 3. Vector Borne Zoonotic Dis (Larchmont, NY) 2011, 11(June (6)):683-689.